帶有 GREB1、ESR1 以及 NCOA2/3 融合基因之婦科肉瘤之病理與功能性研究

Pathologic and Functional Study of Gynecologic Sarcomas Harboring GREB1, ESR1, and NCOA2/3 Gene Fusions

李宛儒(Wan-Ru Lee)

指導教授 ： 鄭永銘

共同指導教授 ： 李仁傑(Jen-Chieh Lee)

國立臺灣大學/醫學院/病理學研究所/碩士(2019年)

https://doi.org/10.6342/NTU201902376

摘要

子宮肉瘤佔所有子宮惡性腫瘤的3％，常見各種特異性融合基因為其特徵，尤其是子宮內膜間質的腫瘤。Growth Regulation by Estrogen in Breast cancer 1 (GREB1) gene 是經由雌激素受體調節的基因，被認為在荷爾蒙相關性組織和癌症中扮演重要角色。Nuclear Receptor Coactivator 2 (NCOA2) gene作為荷爾蒙核受體的共同活化因子，經由後者之結合其反應片段以調節目標基因。它常被發現參與基因轉位與基因融合而與許多癌症相關。我們在病理學鏡檢下發現數個子宮間質肉瘤特徵相似，並藉由次世代定序發現4個有GREB1基因轉位重組的現象，包括GREB1-NCOA2及新穎的GREB1-NR4A3，GREB1-SS18和GREB1-NCOA1轉位重組，此皆經由反轉錄連鎖聚合酶反應和/或螢光原位雜合技術驗證。加上之前報導的病例，GREB1基因重組腫瘤與ESR11基因重組腫瘤相比，與老年婦女高度相關（P = 0.001），且有絲分裂活性更高。藉由功能性實驗，我們發現GREB1-NCOA2融合基因轉錄活性明顯的升高，因此，可能在抑制分化和促進生長扮演重要角色。

關鍵字

子宮肉瘤 ； 融合基因 ； GREB1 ； NCOA2

並列摘要

Uterine sarcomas account for 3% of all uterine malignancies. Some uterine sarcomas, particularly endometrial stromal tumors, contain a variety of specific fusion genes. Growth Regulation by Estrogen in Breast cancer 1(GREB1) is the estrogen receptor-regulated gene. It is thought to play important roles in hormone-responsive tissues and cancers. Nuclear Receptor Coactivator 2(NCOA2) functions as transcriptional coactivators for nuclear hormone receptors, which regulate their target genes upon binding of cognate response elements. NCOA2 has been found to be involved in translocations that result in fusions with other genes in various cancers. By pathologic and by FISH screening, we identified 4 pathologically similar uterine sarcomas harboring rearranged GREB1, which were later found by RNA sequencing to contain GREB1-NCOA2 and novel GREB1-NR4A3, GREB1-SS18, and GREB1-NCOA1 fusions, respectively. All were validated by RT-PCR and/or FISH. Combined with previously reported cases, compared to ESR1-rearranged tumors, GREB1-rearranged tumors involved significantly older women (P=0.001), and tended to be larger and more mitotically active than ESR1-rearranged uterine tumors resembling ovarian sex cord tumor, a tumor entity showing overlapping features with GREB1-rearragned sarcoma. By functional study, we also identified that GREB1-NCOA2 fusion gene dramatically increased the transcriptional activity, and possibly played important roles in inhibiting differentiation and promoting proliferation of sex hormone-responsive cells.

並列關鍵字

uterine sarcoma ； fusion gene ； GREB1 ； NCOA2

參考文獻

1. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic Factors in Early-Stage Uterine Sarcoma - a Gynecologic-Oncology-Group Study. Cancer-Am Cancer Soc. 1993;71(4):1702-9.

2. Giuntoli RL, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89(3):460-9.

3. Oliva E. Cellular Mesenchymal Tumors of the Uterus: A Review Emphasizing Recent Observations. Int J Gynecol Pathol. 2014;33(4):374-84.

4. Kanthan R, Senger JL. Uterine carcinosarcomas (malignant mixed mullerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int. 2011;2011:470795.

5. Lavie O, Barnett-Griness O, Narod SA, Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer. 2008;18(2):352-6.